Innovation Pharmaceuticals Inc (IPIX)

[FarmaZutical]

Thanks a lot for sharing. Along with a possible partnership for P I see this as the elephant in the room:

"A successful Ph2 study of Kevetrin in ovarian cancer will command a much higher valuation for CTIX. If data can further define the mechanism of action of Kevetrin with respect to p53, the possibility of expanding into different cancers should attract global licensing under very attractive terms and all this should happen within in 2017 or earlier!"